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SUMMARY
Osteocytes, the most abundant of bone cells, differentiate while they remain buried within the bone
matrix. This encasement limits their access to nutrients and likely affects their differentiation, a pro-
cess that remains poorly defined. Here, we show that restriction in glucose supply promotes the oste-
ocyte transcriptional program while also being associated with increased mitochondrial DNA levels.
Glucose deprivation triggered the activation of the AMPK/PGC-1 pathway. AMPK and SIRT1 activa-
tors or PGC-1a overexpression are sufficient to enhance osteocyte gene expression in IDG-SW3 cells,
murine primary osteoblasts, osteocytes, and organotypic/ex vivo bone cultures. Conversely, osteo-
blasts and osteocytes deficient in Ppargc1a and bwere refractory to the effects of glucose restriction.
Finally, conditional ablation of both genes in osteoblasts and osteocytes generate osteopenia and
reduce osteocytic gene expression in mice. Altogether, we uncovered a role for PGC-1 in the regula-
tion of osteocyte gene expression.
INTRODUCTION
Of themajor cell types in bone, osteocytesmake upover 90% to 95%of total bone cells in the adult skeleton.
No longer considered passive placeholders in bone, osteocytes have recently emerged asmajor orchestra-
tors of bone remodeling, physical mechanosensors, hematopoietic niche cells, and endocrine regulators of
whole-body metabolism (Dallas et al., 2013; Sato et al., 2013; Karsenty and Olson, 2016). Lower osteocyte
function hasbeendirectly linked tomechanical bone fragility, osteopenia associatedwith agingor diabetes,
chronic kidney disease, and atherosclerosis (Dallas et al., 2013; Lai et al., 2015; Napoli et al., 2017).
Osteocytes derive from osteoblasts through an active and dynamic process involving their embedding in
mineralized osteoid matrices. During osteocytogenesis dramatic morphological changes occur, including
an important restructuring of the cytoskeleton and acquisition of a unique gene expression profile (Bone-
wald, 2011). As osteocytogenesis progresses, we see the downregulation of some osteoblastic genes and
the progressive expression of osteocyte-specific genes such as Dmp1, Fgf23, and Sost (Woo et al., 2011).
Yet the genetic andmolecular mechanisms that govern the differentiation andmaturation of osteocytes are
far from clear.
One of the driving forces of osteoblast-osteocyte transition is likely to be their encasement within a miner-
alized bone matrix. This restricts their access to oxygen and nutrients and can induce modifications in their
metabolic profile (Riddle and Clemens, 2017). The lacuno-canalicular system connects osteocytes between
these matrices and allows those near the surface to interact with osteoblasts and bone-lining cells (Buenzli
and Sims, 2015). However, the mechanisms of diffusion between the bone surface and the osteocytes are
challenged to maintain an adequate supply and exchange of nutrients and metabolic products (Piekarski
and Munro, 1977; Petrov and Pollack, 2003; Wang, 2018). Therefore we can infer that osteoblasts, as they
differentiate into osteocytes, must adapt to a nutrient-restricted environment. For instance, osteocytes are
enriched in proteins involved in hypoxic response, and hypoxic conditions promote the expression of os-
teocytic genes (Hirao et al., 2007; Guo et al., 2010; Dallas et al., 2013).
It has been shown that osteocytes maintain oxidative status utilizing mainly aerobic mitochondrial path-
ways (Frikha-Benayed et al., 2016). In contrast, osteoprogenitors and osteoblasts represent by far the
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most glucose-avid cells in bone with relatively sparse uptake in osteocytes (Dirckx et al., 2018). Glucose is
not only used by osteoblasts but also its uptake synergizes with Runx2 to determine bone formation and
homeostasis throughout life (Wei et al., 2015). Recent studies have further revealed the importance of
aerobic glycolysis for the anabolic effects of parathyroid hormone (PTH) and Wnts (Esen et al., 2013,
2015; Regan et al., 2014). These studies pointed out that modulation of AMPK and/or mTORC1/2 is the
mechanism involved in the functional link between glucose metabolism and bone formation.
AMPK acts as a cellular energy sensor and has a critical role in adaptive metabolic reprogramming. Several
studies demonstrate that AMPK deletion of AMPKa1, b1, or b2 subunits in mice results in reduced trabec-
ular bone without modifying the numbers of osteoclasts and osteoblasts (Quinn et al., 2010). Once active,
AMPK activity leads to higher glucose uptake, autophagy, and mitochondrial biogenesis (Hardie, 2018).
Some of these functions are mediated by the proliferator-activated receptor g co-activator-1 (PGC-1).
PGC-1s are transcriptional co-activators that respond to a number of environmental cues and coordinate
mitochondrial biogenesis and tissue-specific programs of gene regulation (Villena, 2015). Therefore
considering that metabolic rewiring is likely to be crucial for bone cell specification, we hypothesize
that low glucose concentration can induce metabolic and genetic reprogramming, which promotes
osteocytogenesis.
RESULTS
Glucose Restriction Promotes Osteocyte Differentiation
We investigated the effects of different glucose concentrations, the major source of energy in culture
media, on bone cell specification. We differentiated the pre-osteocytic IDG-SW3 cell line and mouse
primary osteoblasts in the presence of 1, 5, or 25 mM glucose. Selected glucose concentrations did
not affect cell viability or proliferation of IDG-SW3 cells (Figures S1A–S1C). Alkaline phosphatase and
alizarin red staining showed the ability of IDG-SW3 cells to differentiate into mature osteoblasts and re-
vealed a decrease in the formation of calcium deposits (alizarin red) when cultured in 25 mM glucose
(Figure 1A). Confluent IDG-SW3 cells differentiated into an early stage of osteocyte specification after
14 days in culture at 37C (Woo et al., 2011). These cells also carry a Dmp1-GFP reporter (expression
of GFP under the control of the osteocyte-specific Dmp1 promoter) that facilitates the follow-up of
the osteoblast-to-osteocyte transition. Our data showed a negative correlation between osteocytic
Dmp1-GFP expression and glucose supply. Low glucose supply enhanced the expression of Dmp1-
GFP, as analyzed by either fluorescence microscopy or fluorescence-activated cell sorting (Figures 1A
and 1B). To further characterize the induced phenotype, we quantified mRNAs associated with osteo-
blasts and osteocytes. Gene expression profiling during the osteoblast-to-osteocyte transition in IDG-
SW3 cells indicated that mRNA levels of osteoblastic genes (Alpl, Col1a1, Bglap, or Atf4) peaked at
the seventh day and decreased thereafter, whereas expression of the osteocytic markers Dmp1
increased at day 14 (Figure 1C). A high-glucose regime reduced the levels of osteoblast genes, such
as Bglap, Osx, or Dkk1. More importantly, glucose restriction (1 mM glucose) significantly increased
the expression of the osteocyte markers Dmp1 and Fgf23 compared with normoglycemia or hyperglyce-
mia (5 and 25 mM glucose, respectively) (Figure 1C). The effects of distinct glucose concentrations in the
osteocytic transcriptional program were independent of changes in the osmotic pressure (Figure S1D).
We also investigated the gene expression profile of osteocytes and bone organotypic cultures main-
tained for 4 and 5 days respectively, with different glucose regimes. As with IDG-SW3 cells, low-glucose
media increased the expression of some osteocytic genes (Dkk1, Dmp1, Fgf23, or Sost) in osteocytes and
bone organotypic cultures (Figures 1D and S1E). Altogether, these data demonstrated that glucose re-
striction favors osteocytic gene expression.
Figure 1. Effect of Glucose Supply in Osteocyte Differentiation
(A) Representative images of alkaline phosphatase staining (ALP), alizarin red staining, and visualization ofDmp1-GFP expression in IDG-SW3 differentiated
for 14 days in the presence of 1, 5, or 25 mM glucose. Cell nuclei were stained with DAPI (blue).
(B) Flow cytometry analysis of Dmp1-GFP expression in IDG-SW3 undifferentiated and differentiated cells for 14 days in the presence of 1, 5, or 25 mM
glucose.
(C) mRNA expression profile of osteoblast and osteocyte gene markers during IDG-SW3 differentiation (at 3, 7, and 14 days) in the presence of 1, 5, and
25 mM glucose.
(D) Quantification of mRNA expression levels in primary osteocytes cultured for 4 days in the presence of 1, 5, or 25 mMglucose. mRNA levels weremeasured
by qRT-PCR and normalized to Tbp expression.
Results are plotted as expression relative to undifferentiated IDG-SW3 or osteocytes cultured in 5 mM glucose (meanG SEM of five to seven independent
experiments). *p < 0.05 and **p < 0.01 using one-way ANOVA. See also Figure S1.
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Glucose Supply Modifies Osteoblast and Osteocyte Metabolism
We then aimed to characterize bone cell metabolism by different glucose concentrations. IDG-SW3 cells
differentiated in low-glucose conditions had decreased intracellular ATP levels compared with normogly-
cemia or hyperglycemia, which suggests a compromised energy supply (Figure 2A). We assayed lactate
released by IDG-SW3 cells during the initial steps of differentiation (24 h) and after complete differentiation
(14 days). As expected, either at 24 h or after differentiation, IDG-SW3 cells cultured in low-glucosemedium
showed a reduction in lactate production, whereas a high-glucose regime raised lactate production values
Figure 2. Metabolic Profile Induced by Glucose Supply
(A) ATP levels in IDG-SW3 after 14 days of differentiation in the presence of 1, 5, or 25 mM glucose.
(B) Quantification of lactate release in predifferentiated IDG-SW3 cultured in 1, 5, or 25 mM glucose media for 24 h, and in
IDG-SW3 differentiated for 14 days in the presence of 1, 5, or 25 mM glucose.
(C) Determination of the maximal uptake capacity for glucose in IDG-SW3 cells differentiated for 14 days in the presence
of 1, 5, or 25 mM glucose.
(D) Determination of routine oxygen consumption, leak respiration (uncoupled), electron transfer capacity (ETS), and
coupled respiration of IDG-SW3 differentiated for 14 days in the presence of 1, 5, or 25 mM glucose. A total of 700,000
IDG-SW3 cells were incubated in the respirometry chamber with 1, 5, or 25 mM glucose in a-MEM without FBS during the
analysis. All results were expressed relative to protein content. Results are plotted as mean G SEM of four to eight
independent experiments.
(E) Flow cytometry analysis of IDG-SW3 cells differentiated for 14 days in the presence of 1, 5, or 25 mM glucose and
labeled with MitoTracker Deep Red.
*p < 0.05, **p < 0.01, and ***p < 0.001 using one-way ANOVA. See also Figure S2.
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(Figure 2B). For a further characterization of metabolic reprogramming, we also analyzed glucose uptake
capacity after differentiation for 14 days in 1, 5, and 25 mM glucose. Glucose uptake was tested at 10 mM
glucose for all conditions. Low glucose exposure significantly increased the uptake capacity for glucose,
whereas glucose-enriched media decreased it (Figure 2C). We also investigated the bone cell metabolism
in primary osteoblasts cultured for 10 days with different glucose concentrations. Mature primary osteo-
blasts cultured in 1 mM glucose were still able to maintain ATP levels and, as IDG-SW3 cells, osteoblasts
increased their glucose uptake capacity in low-glucose conditions (Figures S2A and S2B). Lactate produc-
tion was also increased when cultured in 25 mM glucose (Figure S2C). Therefore mature osteoblasts in cul-
ture can maintain energetic balance and anaerobic glycolysis even at 1 mM glucose. These data suggested
a sparing effect in glucose-restricted conditions, maximizing uptake and reducing lactate release, and vice
versa under hyperglycemic conditions.
We then measured mitochondrial respiration in intact, differentiated IDG-SW3 cells using the different
glucose supplies. These different glucose concentrations were also maintained during the assay as major
energy substrate. We determined routine O2 consumption, leak state (uncoupled respiration after addition
of oligomycin into the assay), electron transfer capacity (determination of electron transfer system [ETS]
after carbonylcyanide-4- (trifluoromethoxy)-phenyl-hydrazone (FCCP)), and coupled respiration. Differences
in respiratory parameters were not significant between groups, and we only observed a slightly increased
routine respiration in cells cultured with 25 mM glucose (Figure 2D). Interestingly, IDG-SW3 cells were able
to maintain O2 consumption under glucose restriction conditions. Moreover, total mitochondrial potential
was unmodified by the different glucose regimes when analyzed by flow cytometry using a mitochondrial
potential-dependent dye (Figure 2E). It is known that routine respiration is controlled byATP turnover and sub-
strate availability (Brand and Nicholls, 2011). Therefore these data suggested that cells adapt to meet energy
demands by increasing glucose uptake and through the diversion of glucose to mitochondrial respiration.
Glucose Restriction Increases the Mitochondrial DNA and Changes Mitochondrial
Morphology
To identify further the changes in energy metabolism induced by glucose supply, we quantified the expres-
sion of genes involved in glycolysis and mitochondrial function. GLUT1 (Slc2a1) is the most expressed
glucose transporter in IDG-SW3 cells during osteocyte specification (Figure S3A). In addition, different
glucose concentrations did not induce a significant change in expression between GLUT family members
(Figures S3B and 3A). IDG-SW3 cells and osteoblasts differentiated under low-glucose conditions had
higher expression of the glycolytic genes Pfkfb3 and Hk2, whereas the expression of Cox4i1 and the genes
involved in mitochondrial fusion/fission Mtf2 and Opa1 did not show significant differences between
distinct glucose regimes (Figures 3A and S3C). As mitochondria are remarkable dynamic organelles that
respond to changes in energy demands, we wondered whether glucose concentration would modify mito-
chondrial content and function. Reduced glucose supply increased the ratio of mitochondrial DNA (mtDNA)
to nuclear DNA (Figures 3B and S3D). This increase in mtDNA was consistent with an increase in the protein
levels of members of the different oxidative phosphorylation (OXPHOS) complexes (Figures 3C and S3E).
Emerging evidence showed that mitochondria continuously adjust their shape, size, and network organi-
zation through fusion or fission events, to regulate their function (Galloway et al., 2012). Confocal images
showed dramatic differences in mitochondrial structure and network among the three conditions. IDG-
SW3 cells and primary osteoblasts differentiated in 1 mM glucose media arranged their mitochondria in
elongated tubules, with higher branching, forming reticular networks (Figures 3D and S3F). In contrast, hy-
perglycemic conditions increased mitochondrial fragmentation with the formation of ring-like structures in
Figure 3. Modification of Glycolytic Gene Expression and Mitochondrial Function Induced by Glucose Supply
(A) mRNA expression levels of glycolytic and mitochondrial genes in IDG-SW3 differentiated for 14 days in the presence of 1, 5, or 25 mM glucose. mRNA
expression levels were measured by qRT-PCR and normalized to Tbp expression. Results were plotted as expression relative to undifferentiated IDG-SW3
(mean G SEM of six independent experiments).
(B) Quantification of mtDNA (tRNA-Glu) in IDG-SW3 differentiated for 14 days in the presence of 1, 5, or 25 mM glucose. mtDNA copy number was measured
by qPCR and normalized relative to nuclear DNA (Dmp1 and Fgf23). Results are plotted as mean G SEM of six independent experiments.
(C) Immunoblot analysis of the expression of Glut1 and mitochondrial complexes in IDG-SW3 differentiated for 14 days in the presence of 1, 5, or 25 mM
glucose.
(D) Visualization of mitochondria in IDG-SW3 differentiated for 14 days in the presence of 1, 5, or 25 mM glucose. Dmp1-GFP was visualized, and
mitochondria were stained with MitoTracker Deep Red.
*p < 0.05, **p < 0.01, and ***p < 0.001 using one-way ANOVA. See also Figure S3.
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differentiated IDG-SW3 and osteoblasts (Figures 3D and S3F). It has been demonstrated that elongated
mitochondria are more resistant to mitophagy and more efficient at producing ATP through enhanced
cristae density and ATP synthase dimerization (Gomes et al., 2011). In addition, it is known that ring-like
and fragmented mitochondria structures arise from cellular stresses (Yu et al., 2006). Therefore these
data suggest that during osteocyte differentiation, glucose restriction stimulates glycolytic pathways
and increases mtDNA and efficiency in an effort to maintain ATP levels.
Glucose Restriction Effects on Osteocyte Gene Expression Depend on AMPK
Nutrient starvation signals through activation of AMPK and mTORC1 energy sensors (Carroll and
Dunlop, 2017). Thus we determined the activation state of signaling pathways likely to be involved in
the metabolic and genetic reprogramming of osteocytes. We analyzed early activation of these pathways
during the first hours of differentiation and after complete differentiation, in IDG-SW3 and primary oste-
oblasts. In response to glucose restriction, AMPK and its substrate acetyl-CoA carboxylase (ACC) became
phosphorylated (Figures 4A, 4B, S4A, and S4B). Similarly, the stress kinase p38-MAPK was also activated
either at 24 h or after 14 days.
Effects of AMPK on mitochondrial biogenesis rely on PGC-1 (PGC1-a and b) expression and activation
(Hardie, 2018). The PGC-1 family of transcriptional co-activators plays a major role in integrating physio-
logical signals into the expression of nuclear-encoded mitochondrial genes (Villena, 2015). Posttransla-
tional modifications that activate PGC-1 members include phosphorylation by AMPK and p38 and
deacetylation by SIRT1 (Fan et al., 2004; Gerhart-Hines et al., 2007; Jager et al., 2007). Therefore to
further characterize the role of AMPK/SIRT/PGC1a/b pathways in osteocyte reprogramming and differen-
tiation, we treated IDG-SW3 cells and bone organotypic cultures with different chemical modulators
of these pathways. The activation of AMPK by AICAR during differentiation increased the expression
of Runx2 and Osx in IDG-SW3 cells and the expression of Dmp1, Fgf23, and Sost osteocyte genes
in both IDG-SW3 and bone organotypic cultures (Figures 4C and 4D). Similarly, the activation of
SIRT1 by SRT2104 treatment induced the expression of late osteocyte markers in both experimental
models. On the other hand, the inhibition of SIRT1 by sirtinol reduced the levels of Osx and Fgf23
in IDG-SW3 cultures. These results suggested that the activation of AMPK/SIRT1 enhances osteocytic
differentiation.
We also evaluated whether induction of mitochondrial fusion and elongation was sufficient for enhance-
ment of osteocytic gene expression. DRP1 is a dynamin-related GTPase that mediates mitochondrial
fission (Galloway et al., 2012). Inhibition of DRP1 by Mdivi-1 increases the number of elongated mitochon-
dria and their reticular network (Cassidy-Stone et al., 2008). Inhibition of mitochondrial fission by Mdivi-1
during osteocytic differentiation reduced the expression ofOsx andDmp1 but only induced the expression
of Sost (Figure 4C). These results suggest that mitochondrial reorganization is not sufficient to enhance
osteocytogenesis.
PGC-1 Mediates Enhanced Osteocytic Gene Expression in Response to Reduced Glucose
Supply
Next, we determined the expression of Ppargc1a and b genes during the osteoblast to osteocyte transition
in IDG-SW3 cells and primary osteoblasts. Proliferative IDG-SW3 cells expressed higher levels of Ppargc1a
compared with Ppargc1b. Moreover, differentiated cells shifted further toward a major expression of
Ppargc1a over Ppargc1b (Figure 5A). Similarly, the ratio of expression between Ppargc1a and Ppargc1b
Figure 4. Signaling Pathways Involved in Metabolic and Genetic Reprogramming of Osteocytes
(A and B) Immunoblots from IDG-SW3 cells cultured in 1, 5, and 25 mM glucose media for 6, 12, and 24 h (A) or after 14 days of differentiation in 1, 5, and
25 mM glucose media (B).
(C) mRNA expression of osteoblastic and osteocytic genes in IDG-SW3 differentiated for 14 days in 5 mM glucose and treated with 0.05 mMAICAR (activator
of AMPK), 0.5 mM SRT2104 (activator of SIRT1), 1 mM sirtinol (inhibitor of SIRT1), and 2.5 mM Mdivi (inhibitor of mitochondrial fission). mRNA levels were
measured by qRT-PCR and normalized to Tbp expression. Results were plotted as expression relative to untreated IDG-SW3 (mean G SEM of five
independent experiments).
(D) mRNA expression of osteoblastic and osteocytic genes in organotypic cultures from mouse femur. Organotypic cultures were maintained in 5 mM
glucose media and treated with 0.05 mM AICAR, 0.5mM SRT2104, and 1 mM sirtinol for 5 days. mRNA levels were measured by qRT-PCR and normalized to
Tbp expression.
Results were expressed as gene expression relative to untreated organotypic cultures (meanG SEM of five independent experiments). *p < 0.05, **p < 0.01,
and ***p < 0.001 using Student’s t test. See also Figure S4.
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in primary osteoblasts and calvarial mRNA was about 3-fold (data not shown). mRNA levels of PGC-1a or
SIRT1 did not change among the three culture conditions in IDG-SW3 (Figure 5B). On the contrary, in pri-
mary osteoblasts, glucose restriction induced Ppargc1a and b mRNA expression (Figure S4C). Ppargc1a
and b play redundant roles by regulating gene expression programs through their interaction with a variety
of transcription factors such as NRF2, ERRa, PPARs, or MEF2. In silico analysis of regulatory motifs present
in the promoters of the osteocyte genesDmp1, Fgf23, and Sost revealed conserved potential binding sites
for PGC-1 co-activated factors. We confirmed the recruitment of PGC-1 to these regulatory regions by
chromatin immunoprecipitation with an anti-PGC-1a antibody. Ectopic expression of PGC-1a and its acti-
vation with AICAR increased PGC-1a occupancy of Fgf23 and Sost promoters in IDG-SW3 cells (Figure 5C).
We also determined whether higher PGC-1a activity could induce expression of these genes. Overexpres-
sion of ectopic PGC-1a in IDG-SW3 and primary osteoblasts led to higher mRNA levels of osteoblastic
(Col1a1, Bglap, Osx) and osteocytic (Dkk1, Fgf23, and Sost) genes (Figure 6A). We also analyzed gene
expression in primary osteoblasts and osteocytes deficient in PGC-1a and PGC-1b. Deletion of Ppargc1a
and b did not affect cell proliferation or viability, although it reduced morphological reorganization and
hampered the increase in mtDNA induced by glucose restriction (Figure S5). Deletion of Ppargc1a and
Ppargc1b in primary osteoblasts or osteocytes decreased the levels of Runx2 and Osx irrespective of the
glucose regime (Figures 6B and 6C). Furthermore, deletion of Ppargc1a and b genes abolished the induc-
tion of the Dmp1, Fgf23, and Sost mRNAs upon glucose restriction. Altogether, these results proved that
PGC-1 co-activators act as regulators of osteocyte gene expression.
Figure 5. PGC1-a Binds to Osteocytic Promoters
(A) mRNA expression levels of the different isoforms of PGC-1 in IDG-SW3 differentiated for 14 days in 5 mM glucose
media. mRNA expression was quantified by qRT-PCR and normalized to Tbp expression. Results are plotted as 2DDCt
(mean G SEM of six independent experiments).
(B) mRNA expression levels of Ppargc1a, Ppargc1b, and Sirt1 during IDG-SW3 differentiation in 5 mM glucose media.
mRNA levels were quantified by qRT-PCR, normalized by Tbp and plotted as expression relative to undifferentiated
IDG-SW3 (mean G SEM of six independent experiments).
(C) Chromatin immunoprecipitation of IDG-SW3 cells infected with control GFP or PGC-1a expression vectors and
differentiated in 5 mM glucose media for 5 days in the presence or absence of 0.5 mM AICAR.
Results were normalized to input chromatin and plotted relative to untreated IDG-SW3 cells infected with control GFP
vector (meanG SEM of four independent experiments). *p < 0.05, **p < 0.01, and ***p < 0.001 using Student’s t test. See
also Figure S4.
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Rearrangement of the cytoskeletal organization is a hallmark of osteocytes. In consequence, we examined
the arrangement of actin cytoskeleton in IDG-SW3 cells cultured in different glucose concentrations as well
as in osteoblasts and osteocytes either wild-type or deficient in Ppargc1a/b. We did not find significant dif-
ferences in any of the conditions (Figure S6).
We further explored the role of Ppargc1a/b in bone formation and homeostasis in mice. Transgenic mice
for Cre under the control of the 2.3-Col1a1 promoter (Dacquin et al., 2002) allowed deletion of Ppargc1a
and b in osteoblasts and osteocytes (hereafter Ppargc1a f/f; Ppargc1b f/f; Col1a1-Cre; knockout [KO]) (Fig-
ures S7A and S7B). Ppargc1a/b deletion did not affect either body weight or femur length. As expected,
Ppargc1a and Ppargc1b mRNA levels in calvaria from KO mice were significantly reduced in both male
and female mice (Figures S7C and S7D). We visualized bone formation in male and female mice in distal
femurs by micro-computed tomography scanning and histological analysis. In 8 week-old mice, deletion
of Ppargc1a and Ppargc1b led to a decrease in both trabecular and cortical bone architecture. KO male
mice presented lower cortical bone volume (BV) associated with reduced cortical thickness, whereas
bone perimeter around the midshaft was not affected (Figure 7A). In addition, distal femurs in males
also presented less trabecular bone volume (BV/TV) resulting from a significantly lower trabecular number
(Tb.N) and trabecular thickness (Tb.Th) (Figure 7A). Trabecular analysis of distal femurs in KO females also
showed a significant reduction in BV/TV, Tb.N, and Tb.Th. However, reduction in cortical bone parameters
were lower in magnitude and did not reach significant differences (Figure 7B). To clarify the underlying
reason for the osteopenic phenotype of the KO mice, we analyzed the expression of osteoblast and oste-
ocyte genes from calvaria. KO male and female mice displayed a reduced expression of osteocyte genes,
including Dmp1, Fgf23, and Sost, and increased levels of osteoblastic genes such as Bglap, Runx2, or Osx
(Figure 7C). Reduced osteocyte gene expression occurs without significant changes in either the density of
osteocytes per bone area or the number of empty lacunae in cortical bone (Figures S8 and S9). Mice defi-
cient for Ppargc1a/b showed reduced Rankl/Opg ratio of expression in calvaria (Figure S10). Similar results
were obtained in osteocytes deficient in Ppargc1a/b. These data suggest that although Ppargc1a/b affects
the expression of Rankl and Opg in osteocytes, osteopenia in young Ppargc1a/b-deficient mice does not
arise for increased osteoclastogenesis induced directly by an increased Rankl/Opg ratio. In conclusion, our
data demonstrate the relevant role of PGC-1 in co-activation of the osteoblast and osteocyte transcrip-
tional programs.
DISCUSSION
In this study, we identified that a reduced supply of glucose facilitates the expression of osteocytic genes in
osteoblast/osteocyte precursors. These effects took place in parallel with an increased mtDNA. Glucose
reduction triggers the activation of theAMPK/PGC-1 pathwaywhereas AMPK and SIRT1 activators were suf-
ficient to increase osteocyte gene expression. Osteoblasts and osteocytes deficient in Ppargc1a and bwere
refractory for glucose restriction effects, whereas mice deficient in both genes were osteopenic. Our data
strongly support modulation of the metabolic state as a strategy for the differentiation of bone cells.
In recent years, several studies have demonstrated that metabolism of osteoblast lineage cells is pro-
grammed to optimize energy production to fulfill functional demands throughout their life cycle (Riddle
and Clemens, 2017). Early stage of osteoblast specification relies on glycolysis to generate ATP, initiate
collagen synthesis, and stabilize RUNX2 expression (Wei et al., 2015; Guntur et al., 2018). Accordingly, mo-
lecular signals that determine osteoblast specification, such as Wnt, PTH, or Hypoxia-inducible factor 1
(HIF-1), also promote aerobic glycolysis in osteoblast progenitors (Esen et al., 2013, 2015; Regan et al.,
2014; Dirckx et al., 2018). However, in the adult human skeleton, about 42 billion osteocytes are entrapped
in their own mineralized matrix while being connected by cytoplasmic projections with a total length of
175,000 km. These resident osteocytes leave space for just 24 mL extracellular fluid (Buenzli and Sims,
Figure 6. Role of PGC-1 in Osteocyte Differentiation
(A) mRNA expression levels of IDG-SW3 cells (left) and primary osteoblasts (right) infected with GFP or PGC-1a expression vectors and differentiated in 5mM
glucose media for 5 days. mRNA expression levels were measured by qRT-PCR and normalized to Tbp expression. Results were plotted as expression
relative to cells infected with GFP vector (mean G SEM of six to eight independent experiments).
(B andC)mRNA expression levels of osteocytic and osteoblastic genes in primary osteoblasts (B) and primary osteocytes (C) wild-type and knockout for PGC-
1a/b. Osteoblasts and osteocytes were isolated from calvarias obtained from Ppargc1a/bfl/flmice and infected with pMSCV-Puro or pMSCV-puro-Cre-ERT2
vectors. Infected cells were cultured for five days in 1, 5, or 25mMglucosemedia.mRNAexpression levels weremeasuredby qRT-PCR and normalized to Tbp.
Results are plotted as expression relative to control infection (meanG SEM of six independent experiments). *p < 0.05, **p < 0.01, and ***p < 0.001 using
Student’s t test. See also Figures S5 and S6.
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2015). Therefore osteocyte transition and network formation processes are likely to demand high levels of
energy in a nutrient-restricted environment. Our data demonstrate that a shift of the metabolic machinery
toward a higher mitochondrial function occurs during the transition of osteoblasts into osteocytes under
conditions of glucose restriction. Mitochondria optimize their morphology to cope with reduced caloric
supply. Correspondingly, osteocytes in vivo have been shown to have numerousmitochondria and tomain-
tain normal oxidative status through mitochondrial pathways (Frikha-Benayed et al., 2016). Osteocytes
contribute little to glucose consumption inmurine bones compared with osteoprogenitors and osteoblasts
(Dirckx et al., 2018). Furthermore, it has been recently shown that bone accumulates a significant fraction of
postprandial fatty acids and that suppression of fatty acid oxidation in mature osteoblasts and osteocytes
impairs bone accrual (Kim et al., 2017). This link between metabolic reprogramming and cellular specifica-
tion was already well established for other models of cell specification. For example, higher mitochondrial
biogenesis and function is related to the final stage of neurogenesis, astrocytogenesis, hepatic differenti-
ation, and erythropoiesis (Agostini et al., 2016; Xing et al., 2017). On the other hand, we also found that
hyperglycemic conditions modify mitochondrial organization and impair osteoblast and osteocyte gene
expression. Hyperglycemicmicroenvironments have been associated with a reduction in osteocyte number
and function (Rinker et al., 2014), whereas bone turnover and remodeling have been found to be compro-
mised in patients with diabetes (Kalaitzoglou et al., 2016).
Consistent with its role as regulator of energy homeostasis, we found an inverse correlation between AMPK
activity and glucose supply. These results are in agreement with recent evidence showing that AMPK
became activated by phosphorylation at Thr172, by sensing not only low cellular energy but also low
glucose supply (Lin and Hardie, 2017; Zhang et al., 2017). Activation of AMPK with AMP analogs in normo-
glycemia was sufficient to induce osteocyte gene expression in IDG-SW3 cells and organotypic bone cul-
tures. Indeed, studies using whole-body and osteoblast-specific genetic abrogation of AMPK activity
showed lower cortical and trabecular bone density and enhanced bone turnover (Jeyabalan et al., 2012;
Kanazawa et al., 2018). It has been shown that AMPK activation decreases Rankl and increases Sost expres-
sion in osteocytes to delicately coordinate bone turnover (Jeyabalan et al., 2012). Our data also demon-
strated that activation of SIRT1 by SRT2104 led to increased osteocyte gene expression program in IDG-
SW3 cells and organotypic bone cultures. An increase in bone mineral density was observed in mice fed
on a diet supplemented with SRT2104 and shown to be Sirt1 dependent (Mercken et al., 2014). The bene-
ficial role of SIRT1 in bone formation and remodeling were further confirmed in whole-body and osteoblast-
specific Sirt1-deficient mice, which displayed low bonemass phenotype (Cohen-Kfir et al., 2011). Moreover,
SIRT1 activation gave protection against osteoporosis in both mice and humans (Ornstrup et al., 2014).
We identified a key role of PGC-1, downstream of AMPK, in the coordination of mitochondrial biogenesis
and osteocyte specification in cultured cells and murine models. Lessons from other tissues indicate that
PGC-1a and PGC-1b have a redundant transcriptional role because noticeable phenotypes were only
observed when the expression of both co-activators was abolished (Villena, 2015). Our data show that
PGC-1a/b also have a fundamental role in osteoblast and osteocyte function and bone homeostasis.
Ppargc1a was expressed in osteoblasts and osteocytes in preference to Ppargc1b. Moreover, osteo-
blast-to-osteocyte transition further increased this tendency. Interestingly, PGC-1b is the main member
of the PGC-1 family expressed in osteoclasts and is specifically required for osteoclast function (Wei
et al., 2010; Zhang et al., 2018). The functional and therapeutic implications of such cell-type-specific co-
activator preferences await further research. For instance, the action of different activators of PGC-1a in
osteoblasts prevents bone loss in type 2 diabetes models without improving diabetes in a PGC-1a-depen-
dent manner (Khan et al., 2015).
PGC-1 co-activates specific transcription factors, including NRF1, NRF2, PPARs, ERa, ERRa, and MEF2C
(Villena, 2015). Co-activation of ERa could account for the milder osteopenic phenotypes that we
Figure 7. Bone phenotype of Ppargc1a/b Conditional Knockout Mice
(A and B) Micro-computed tomographic analysis and representative images of femurs obtained from male (A) and female (B) Ppargc1a/bf/f;Col1a1-Cre and
control (Ppargc1a/bf/f) mice. Results were plotted as mean G SEM of 8–11 independent animals.
(C) mRNA expression levels of osteocytic and osteoblastic genes in calvaria obtained from PGC1a/b conditional knockout (Ppargc1a/b f/f;Col1a1-Cre) and
control mice.
Results are plotted as meanG SEM of eight independent animals. mRNA expression levels were measured by qRT-PCR and normalized to Tbp expression.
*p < 0.05, **p < 0.01, and ***p < 0.001 using Student’s t test. B.Ar, bone area; B.Pm, bone perimeter; Ct.Th, cortical thickness; Tb.N, trabecular number;
Tb.Sp, trabecular spacing; Tb.Th, trabecular thickness; See also Figures S7–S10.
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obtained in female mice because osteocyte-specific deletion of ERa has been shown to affect bone min-
eral density only in male mice (Lee et al., 2003; Windahl et al., 2013). Co-activation of diverse transcrip-
tion factors by PGC-1 has been shown to deeply affect developmental transcriptional programs such as
erythropoiesis, chondrogenesis, and differentiation of hepatocytes, cardiomyocytes, and brown adipo-
cytes (Wanet et al., 2017; Cui et al., 2014). Our data show that this would also be the case for osteocyto-
genesis. For instance, PGC-1a binds to the Fgf23 or Sost gene promoters, whereas overexpression and
loss-of-function experiments produce effects on the expression of Dmp1, Dkk1, Fgf23, Sost, or Osx
genes. We found numerous conserved binding sites for known transcription factors in the promoter
and enhancer regions of Fgf23, Sost, Dmp1, or Osx genes that could mediate their regulation by
PGC1-a. For instance, it is known that ERa, NRF2, PPARs, ERRa, and MEF2C positively regulate osteocyte
gene expression (Kramer et al., 2012; Stechschulte et al., 2016). Therefore PGC-1s are able to co-activate
a number of transcription factors with universal and osteocyte-specific functions. Altogether, we have un-
covered a central role of PGC-1-mediated transcriptional program required for osteoblast and osteocyte
function.
Limitations of Study
Our results demonstrate that glucose restriction promotes osteocytic gene expression through PGC-1-
mediated transcriptional co-activation. However, at present, the transcription factors directly involved in
this co-activation in specific gene promoters are still unknown and require further investigation. In addition,
Ppargc1a/b is deleted in both osteoblasts and osteocytes in our mouse model. Therefore we are unable to
distinguish the relative contribution in bone homeostasis in vivo of PGC-1 expressed in osteoblasts and
osteocytes.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.04.015.
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 Figure S1. Glucose supply is responsible for changes in gene expression, related to 
Figure 1.  (A and B) TUNEL staining of IDG-SW3 differentiated for 14 days in the 
presence of 1, 5 or 25 mM glucose. Representative images (A) and quantitative analysis 
(B) of TUNEL staining. Results are plotted as mean ± SEM of three independent 
experiments. (C) Proliferation rate of IDG-SW3 differentiated for 14 days in presence of 
1, 5 or 25 mM glucose. Results are expressed as percentage of BrdU+ cells. Data are 
plotted as mean ± SEM of three independent experiments. (D) Quantification of mRNA 
expression levels in IDG-SW3 cells differentiated for 14 days in the presence of 1, 5 or 
25 mM glucose or in the presence of 1mM glucose plus 24 mM mannitol and 5 mM 
glucose plus 20 mM mannitol. Results are plotted as expression relative to IDG-SW3 
cells cultured in 5 mM glucose and statistical analysis was performed between conditions 
with or without mannitol (E) Quantification of mRNA expression levels in organotypic 
cultures from mouse femur maintained in 1, 5 or 25 mM glucose media. Results are 
plotted as expression relative to organotypic cultured maintained in 5 mM glucose media.  
mRNA levels were measured by RT-qPCR and normalized to Tbp expression. Results 
are plotted as mean ± SEM of six independent experiments. *p<0.05, **p<0.01 and 
***p<0.001 using Student´s t-test. 
Figure S2. Metabolic profile in primary mature osteoblasts under different glucose 
supplies, Related to Figure 2. (A) ATP levels in osteoblasts after 10 days of 
differentiation in the presence of 1, 5 or 25 mM glucose. (B) Determination of the 
maximal uptake capacity for glucose in osteoblast differentiated for 10 days in the 
presence of 1, 5 or 25 mM glucose. Glucose uptake was tested at 10 µM glucose for all 
conditions. (C) Quantification of lactate release in osteoblasts differentiated for 10 days 
in the presence of 1, 5 or 25 mM glucose.  
Figure S3. Changes in glycolytic gene expression and mitochondrial function 
induced by different glucose concentrations, Related to Figure 3. (A) mRNA 
expression levels of the different GLUT family members  (SLC2a) in IDG-SW3 
differentiated for 14 days in 5 mM glucose media. mRNA expression was quantified by 
RT-qPCR and normalized to Tbp expression. Results are plotted as 2-ΔCt (mean ± SEM 
of six independent experiments). (B) mRNA expression levels of  Slc2a2, Slc2a3 and 
Slc2a4 during IDG-SW3 differentiation in 1, 5 and 25 mM glucose media. mRNA levels 
were quantified by qRT-PCR, normalized by Tbp and plotted as expression relative to 
undifferentiated IDG-SW3 (mean ± SEM of six independent experiments). (C) mRNA 
expression levels of glycolytic and mitochondrial genes in primary osteoblasts 
differentiated for 10 days in the presence of 1, 5 or 25 mM glucose. Results are plotted as 
expression relative to undifferentiated primary osteoblasts (mean ± SEM of six 
independent experiments).  (D) Quantification of mtDNA in primary osteoblasts 
differentiated for 10 days in the presence of 1, 5 or 25 mM glucose. Results are plotted as 
expression relative to undifferentiated primary osteoblasts (mean ± SEM of four 
independent experiments). (E) Analysis of the levels of mitochondrial complexes in 
primary osteoblasts differentiated for 10 days in the presence of 1, 5 or 25 mM glucose.  
(F) Visualization of mitochondria in primary osteoblasts differentiated for 10 days in the 
presence of 1, 5 or 25 mM glucose. *p<0.05, **p<0.01 and ***p<0.001 using one-way 
ANOVA. 
Figure S4. Signaling pathways involved in glucose restriction in osteoblasts, Related 
to Figure 4 and 5. (A and B) Immunoblots from primary osteoblasts during the first 24 
hours of differentiation in 1, 5 or 25 mM glucose media (A) or after 10 days of 
differentiation in 1, 5 and 25 mM glucose media (B). (C) mRNA expression levels of 
Ppargc1 isoforms and Sirt1 in primary osteoblasts differentiated for 10 days in 1, 5 or 25 
mM glucose media. Results are plotted as ΔΔCt relative to undifferentiated osteoblasts at 
day 0 (mean ± SEM of five independent experiments). 
Figure S5. Loss of PGC-1α/β does not affect cell viability but abolishes the increase 
in mitochondrial DNA induced by glucose restriction, Related to Figure 6. (A and B) 
TUNEL staining of primary osteoblasts wild-type (WT) and knock-out (KO) for 
Ppargc1a/b. Representative images (A) and quantitative analysis (B) of TUNEL staining. 
Results are plotted as mean ± SEM of three independent experiments. (C) Proliferation 
rate of primary osteoblasts wild-type and KO for Ppargc1a/b. Results are expressed as 
percentage of BrdU+ cells. Data are plotted as mean ± SEM of three independent 
experiments. (D) Visualization of mitochondria in primary osteoblasts wild-type and KO 
for Ppargc1a/b differentiated for 10 days in the presence of 1, 5 or 25 mM glucose. (E) 
Quantification of mtDNA in primary osteoblasts, wild-type and KO for Ppargc1a/b, 
differentiated for 10 days in the presence of 1, 5 or 25 mM glucose. Results are plotted 
relative to the content of wild type osteoblasts cultures at 5 mM glucose as mean ± SEM 
of four independent experiments.  *p<0.05, **p<0.01 and ***p<0.001 using one-way 
ANOVA. 
Figure S6.  Different glucose supply or deletion of Ppgarc1a and Ppgarc1b does not 
alter actin cytoskeleton organization, Related to Figure 6. (A) Representative images 
of Maximum Intensity Projection of IDG-SW3 differentiated in 1, 5, or 25 mM glucose 
media for 14 days and stained with Alexa 488‐phalloidin (red) and DAPI (blue) (B) 
Maximum Intensity Projection of primary osteoblasts wild-type and KO for Ppargc1a/b 
stained with Alexa 488‐phalloidin (red) and DAPI (blue) (C) Maximum Intensity 
Projection of primary osteocytes wild-type and KO for Ppargc1a/b stained with Alexa 
488‐phalloidin (red) and DAPI (blue). 
Figure S7.  Ppgarc1a and Ppgarc1b expression levels in Ppargc1a/b deficient (KO) 
mice, Related to Figure 7.  (A). mRNA expression levels of Ppgarc1a and Ppgarc1b in 
primary osteoblast wild-type and KO for Ppargc1a/b. Results were plotted as mean ± 
SEM of six independent experiments. (B) mRNA expression levels of Ppgarc1a and 
Ppgarc1b in primary osteocytes wild-type and KO for Ppargc1a/b. Results were plotted 
as mean ± SEM of six independent experiments. (C and D) mRNA expression levels of 
Ppgarc1a and Ppgarc1b in calvaria obtained from Ppargc1a/b conditional knockout 
(Ppargc1a/b f/f;Col1a1-Cre) and control male (C) and female (D) mice. Results were 
plotted as mean ± SEM of eight independent animals. mRNA expression levels were 
measured by RT-qPCR and normalized to Tbp expression. *p<0.05, **p<0.01 and 
***p<0.001 using Student´s t-test. 
Figure S8.  Histological analysis of femurs of Ppgarc1a and Ppgarc1b-deficient mice, 
Related to Figure 7. Representative images of longitudinal sections of femur from wild 
type (WT) and Ppargc1a/b knock-out (KO) mice stained with hematoxylin and eosin. 
Images were taken at 4x and 10x magnification.  
Figure S9, Related to Figure 7. (A) Representative images of longitudinal sections from 
middle and distal femur from wild type (WT) and Ppargc1a/b knock-out (KO) mice 
stained with Masson's trichrome stain. Images were taken at 2x and 20x magnification. 
(B) Osteocyte number normalized by bone area. Results are shown as mean ± SEM of 12 
different fields from 8 different animals.  
Figure S10, Related to Figure 7. (A) mRNA expression levels of Rankl, Opg and 
Rankl/Opg expression ratio in primary osteocytes wild-type and KO for Ppargc1a/b 
cultured in 1, 5, and 25 mM glucose media. Results were plotted as mean ± SEM of three 
independent experiments. (B and C) mRNA expression levels of Rankl, Opg and the 
Rankl/Opg expression ratio in calvaria obtained from Ppargc1a/b conditional knockout 
(Ppargc1a/b f/f;Col1a1-Cre) and control male (B) and female (C) mice.   
 
TRANSPARENT METHODS 
Cell cultures 
IDG-SW3 cells (obtained from Dr. L. Bonewald) were cultured as previously 
described (7). Briefly, IDG-SW3 were maintained and expanded in proliferative 
conditions (33°C in αMEM with 5 mM glucose, 10% FBS, 2 mM glutamine, 1 mM 
pyruvate, 100 U/ml penicillin, 0.1 mg/ml streptomycin and 50 U/ml IFN-γ) on type I 
collagen-coated plates. To induce osteogenesis, cells were seeded on type I collagen-
coated plates and cultured in osteogenic media (37°C in αMEM with 10% FBS, 1, 5, or 
25 mM glucose, 2 mM glutamine, 1 mM pyruvate, 100 U/ml penicillin and 0.1 mg/ml 
streptomycin with 50 µg/ml ascorbic acid and 4 mM β-glycerophosphate, in the absence 
of IFN-γ).  
Primary osteoblasts were isolated from calvaria as previously described (24). 
Briefly, calvaria was dissected from P1-P4 pups, and sutures and soft tissue were 
discarded. A total of 5 to 10 calvariae were pooled and serially digested in α-MEM, 
containing trypsin (0.025%)/collagenase II (1 mg/mL). The product of the first 5 minutes 
of digestion was discarded, while the product of a double 20-minute digestion was 
centrifuged and seeded on 60-mm culture plates. Cells were used between passages 4 to 
6. Osteoblasts were cultured in osteogenic media (as above) and the concentration of 
glucose adjusted to 1, 5, or 25 mM.  
For bone organotypic cultures, bone pieces from mice femurs were digested in 
DMEM containing collagenase II (1mg/ml) for 2h at 37ºC in a shaking water bath. Then, 
bone pieces were rinsed, plated and incubated overnight in osteogenic media. The next 
day, bone pieces were washed 4 times with PBS and incubated in osteogenic media for 5 
days.   
Primary osteocytes were isolated with a protocol derived from Shah et al. (Shah 
et al. 2016, Bonekey Rep. 5:838). Briefly, mice limbs (tibiae, femur and humeri) and 
calvariae from 5 mice were pooled, cut and serially digested on a rotating shaker at 37°C. 
Bone pieces were incubated in collagenase solution (trypsin (0.025%)/collagenase II (1 
mg/mL) in α-MEM) for 25 min. The solution was discarded, and the bone pieces were 
washed in PBS. This was repeated two more times, for a total of three digestions 
(digestions 1 to 3). Then, bone pieces were incubated with EDTA solution (5 mM EDTA 
in PBS containing 1% BSA, pH = 7.4) for 25 min. The solution was discarded (digestion 
4), and the bone pieces were washed in PBS (digestion 4). Bone pieces were incubated 
with collagenase solution for 25 min, the solution was discarded, and the bone pieces 
were washed in PBS (digestion 5). Bone pieces were incubated with EDTA solution for 
25 min, the solution was discarded, and the bone pieces were washed in PBS (digestion 
6). Bone pieces were incubated with collagenase solution for 25 min, the solution was 
kept for cell plating, and the bone pieces were washed in PBS (digestion 7). Bone pieces 
were incubated with EDTA solution for 25 min, the solution was kept for cell plating, and 
the bone pieces were washed in PBS (digestion 8).  Bone pieces were incubated with 
collagenase solution for 25 min, the solution was kept for cell plating (digestion 9). 
Digestions 7 to 9 were combined and spun down at 200xg for 5 min.  The cell pellet was 
resuspended in α-MEM culture medium and plated on type-I rat tail collagen coated 
culture plates. Osteocytes were cultured in α-MEM supplemented with 5% FBS, 5% calf 
serum, 1mM pyruvate, 100 U/ml penicillin and 0.1 mg/ml of streptomycin. Cells were 
maintained at 37°C and 5% CO2 in a humidified incubator up to 7 days. 
Animal model 
We used eight-week-old C57BL/6 female and male mice. All animal had ad libitum 
access to food (Teklad, 2014: Harlan‐Teklad, Indianapolis, IN, USA) and water. Mice 
were maintained at 22-24ºC on a 12-hour light/12-hour dark cycle. All procedures were 
approved by the Ethics Committee for Animal Experimentation of the University of 
Barcelona and the Generalitat de Catalunya. Osteoblast-specific Ppargc1a/b-deficient 
mice (Ppargc1a/b;Col1a1-Cre) were generated by crossing heterozygous Col1a1-Cre 
mice (Tg(Col1a1-cre)1Kry(21) with mice carrying loxP sites flanking exons 4 and 5 of 
the Ppargc1a (25) and exons 4 and 5 of Ppargc1b alleles (26). Ppargc1a/b f/f;Col1a1-Cre 
(KO) mice were fertile and born in the Mendelian ratio, and they were crossed with 
Ppargc1a/b f/f to obtain experimental (Ppargc1a/b f/f;Col1a1-Cre) and control 
(Ppargc1a/b f/f) mice.  
Retroviral transduction 
Retroviral pMSCV-PGC-1α (generated from pcDNA4-PGC-1α from Addgene) 
and pMSCV-GFP control virus were used for PGC1α overexpression in primary 
osteoblasts and IDG-SW3 cells. After infection, cells were cultured for five days in 
osteogenic media. Retroviral pMSCV-puro-Cre-ERT2, pMSCV-puro and pMSCV-GFP 
virus were used for Ppargc1a/b deletion assays in primary osteoblasts from Ppargc1a/b 
f/f mice. Puromycin (5µg/ml) was used for selection of infected cells. 24 hours after 
selection, tamoxifen was added at 1µM for 48 hours. Cells were then cultured for five 
more days in osteogenic media. 
Alkaline phosphatase and Alizarin Red staining 
For alkaline phosphatase, staining solution was added to the cells and incubated 
at room temperature for 30 minutes in the dark. For Alizarin Red staining, fixed cells 
were incubated with Alizarin Red staining solution at room temperature in the dark for 
45 minutes.  
Flow cytometry 
Differentiated IDG-SW3, osteoblasts and osteocytes were rinsed twice with PBS. 
Cells were incubated with 0.25% Trypsin and 0.02% EDTA at 37ºC for 5-10 min, until 
cells became rounded and started to detach. Cell suspensions were collected and 
centrifuged at 150g for 5 min. Cell pellets were rinsed three times with PBS and 
resuspended in PBS containing 1, 5, or 25 mM glucose, 2 mM glutamine and 1 mM 
pyruvate. Before flow cytometry analysis, cell suspensions were filtered with a 0.70 μm 
nylon mesh to remove aggregates. Cell viability was assessed with 7-ADD, ensuring that 
the analyzed population of cells was alive. 
Dmp1-GFP expression 
Expression of Dmp1-GFP in IDG-SW3 was evaluated after 14 days of 
differentiation by fluoresce microscopy in a Leica DMIRB fluoresce microscope and flow 
cytometry in a DB FACS Canto II flow cytometer. 
Cell proliferation assay 
IDG-SW3, osteoblast and osteocyte proliferation was evaluated using BrdU 
labeling (BD, CA, USA), following the manufacturer’s protocol. Briefly, 2 × 104 cells 
were seeded and cultured for 14- 10 or 7 days. Then, BrdU (10 µM) was added to the 
medium for 6 hours. Cells were harvested, fixed and permeabilized. The samples were 
treated with DNase (300 μg/mL in PBS) for 1 hour at 37ºC. BrdU was stained with APC-
conjugated anti-BrdU antibody. Cells were analyzed in a DB FACS Canto II flow 
cytometer. 
Cell death detection assay 
DNA cleavage was assessed by the TUNEL assay as described by the 
manufacturer (Roche Molecular Biochemicals). Briefly, IDG-SW3, osteoblast or 
osteocytes were cultured for 14, 10 or 7 days and then fixed with 4% paraformaldehyde 
in PBS pH 7.4 at room temperature for 1 h. Cells were permeabilized with 0.1% Triton 
X-100 in sodium citrate buffer for 2 min at 4 °C and incubated with TUNEL reaction 
mixture for 1 h at 37 °C. Total DNA was stained with DAPI (1μg/ml, D9542, Sigma) 
diluted in PBS for 20 min at room temperature. Coverslip were mounted with 
ProLong®Gold antifade reagent (P36939, Life Technologies). DNA damage was 
visualized by fluoresce microscopy in a Nikon E800 microscope. Images were analyzed 
using ImageJ software.  
Fluorescence confocal imaging 
IDG-SW3 and primary osteoblasts were cultured in differentiation media for 14 and 
10 days, respectively. For Mitocondria visualization, cell cultures were stained with 
250nM Mitotracker-Deep-Red (ThermoFisher) for 30 minutes at 37ºC. Then, the cells 
were examined in a Zeiss LSM 880 laser scanning confocal spectral microscope equipped 
with an incubation control system (37 °C, 5% CO2). Images corresponding to single 
confocal sections were taken using a 63x oil immersion objective lens. Images were 
analyzed using ImageJ software. 
For the staining of actin filaments, cells were fixed in 4% paraformaldehyde in PBS 
for 15 min at room temperature, washed twice in PBS, permeabilized for 15 min in PBS 
containing 0.1% Triton X-100, and then blocked in PBS containing 1% BSA for 30 min. 
To visualize F-actin, cells were incubated with 7.5 units of Alexa Fluor 488 phalloidin 
(Invitrogen) for 1 hour and washed three times with PBS. DNA was stained with DAPI 
(1μg/ml, D9542, Sigma). Coverslips were air dried and mounted with ProLong Gold 
antifade reagent (P36939, Life Technologies). Several z-stack images of  0.4 μm were 
acquired using Zeiss LSM 880 laser scanning confocal spectral microscope and processed 
using ZEN software 2010 (Zeiss) to obtain a Maximum Intensity Projection for each Z- 
stack series.  
Gene expression 
Total RNA was isolated from mouse calvaria, primary osteoblasts or IDG-SW3 
cells using TRIsure reagent (Bioline, London, UK). Purified RNA was reverse-
transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA, USA). Quantitative PCR was carried out using the ABI 
Prism 7900 HT Fast Real-Time PCR System and a Taqman 5′-nuclease probe method 
(Applied Biosystems) with SensiFAST Probe Hi-ROX Mix (Bioline). All transcripts 
were normalized to TATA binding protein (Tbp) expression.  
Glucose uptake 
The uptake of 2-deoxyglucose was studied in IDGs  grown for 14 days in 1, 5, and 
25 mM glucose in osteogenic media. Cells were washed four times with pre-warmed PBS, 
incubated with PBS containing 50Ci/mmol of 2-deoxy-D-[G-3H] glucose and 10µM of 
cold 2-deoxy-D-glucose for 5 min at 37 ºC. Monolayers were washed 4 times with cold 
PBS and lysates were obtained in 0.4M NaOH.  
Lactate assay 
L-lactate was determined using an enzymatic reaction based on the oxidation of 
L-lactate to pyruvate by lactate dehydrogenase. Samples were diluted by 1:20 with 
reaction buffer (0.3M hydrazine sulphate, 0.87M Glycine, 2.5 mM NAD+, 0.19M EDTA, 
pH 9.5). NADH concentration was determined by measuring absorbance at 340 nM using 
Fluostar Optima BMG Labtech at 0 and 20 minutes after starting reaction.  
Intact cell respirometry 
Mitochondrial function of intact cells was measured by high-resolution 
respirometry (Oxygraph-2k, Oroboros Instruments). IDG-SW3 cells were cultured in 
differentiation media with the indicated glucose concentration for 14days. Cells were 
trypsined and resuspended again in differentiation media with 1, 5, or 25 mM glucose 
without FBS. 700,000 cells were added to the experimental chamber. Endogenous routine 
respiration was measured with 1, 5, and 25 mM glucose as substrates. Following 
stabilization of routine respiration, ATP synthesis was inhibited with 1µg/ml of 
oligomycin to analyze respiratory uncoupling. Next, carbonylcyanide-4-
(trifluoromethoxy)-phenyl-hydrazone 1 μM (FCCP) was titrated to achieve maximum 
flux through the electron transfer system (ETS). Finally, respiration was inhibited by the 
sequential addition of rotenone (0.1 μM) and antimycin A (2.5 μM). The remaining 
O2 flux after inhibition with antimycin A (O2 flux independent of the electron transfer 
system) was subtracted to calculate the different respiratory states. Oxygen flux values 
were expressed relative to protein content determined by the BCA method. 
ATP bioluminescence assay 
ATP was detected by luciferin-luciferase-ATP reaction. IDGs were lysed in 500µl 
of boiling water. Extracts were spin at 12000g and 4°C for 5 minutes and 10 µl of 
supernatant were used for ATP determination. Luciferin-luciferase assay was performed 
following the manufacturer's recommendations (rLucHS, Biovision).  
Western blot assay 
Identification of proteins from cell extracts was performed by immunoblotting 
against pp38, pEIF2α, pS6, LC3, ATF4, SIRT1, pAMPK, pACC, PGC1α, Oxphos, 
GLUT1 or α-TUBULIN), diluted at 1:1000. Immuno-reactive bands were detected with 
horseradish-peroxidase-conjugated secondary antibodies and an EZ-ECL kit (Biological 
Industries, Cromwell, CT, USA). 
Chromatin immunoprecipitation assay 
ChIP assay was performed as previously described (27). IDG-SW3 cells were 
retrovirally-infected with Ppargc1a constructs. Cells were cultured for 5 days and fixed 
in 1% formaldehyde for 10 minutes. ChIP was carried out using 1 μg of anti-PGC-1α 
(Abcam) or anti-IgG (Upstate) and purified with 20 μl Magna ChIP Protein A+G 
Magnetic Beads (Millipore). Purified DNA fragments were analyzed by qPCR with 
SYBR Green. The primers used for the analysis for Dmp1, Fgf23 and Sost gene promoters 
are detailed in (Supplementary Table 2). 
Determination of mtDNA by qPCR 
Two µg of total DNA were used for mitochondrial DNA determination by qPCR. 
Primers for a mitochondrial DNA gene (tRNA-Glu) and a nuclear DNA gene (Fgf23) were 
used. The cycling conditions used were 43 cycles of 30 seconds at 95°C, 30 seconds at 
70ºC, and 60 seconds at 72°C. 
µCT analysis 
Femurs from mice were dissected, cleaned of soft tissue, and fixed in 4% 
paraformaldehyde (PFA) for 48 hours. High‐resolution images from the femur were 
acquired using a microCT imaging system (Skyscan 1076, Bruker microCT, Kontich, 
Belgium) in accordance with the recommendations of the American Society of Bone and 
Mineral Research (ASBMR). Samples were scanned in air at 50 kV and 200 µA with an 
exposure time of 800 ms, using a 1‐mm aluminium filter and an isotropic voxel size of 
9 µm. Two‐dimensional images were obtained every 1° for 180° rotation and were 
subsequently reconstructed using NRecon reconstruction software and analyzed with CT‐
Analyzer (SkyScan). For trabecular measurements, manual VOI was employed, starting 
at 100 slices from the distal growth plate of the femur and extending to the diaphysis for 
150 slices. Cortical measurements were performed by delineating the femur medial cortex 
for 100 slices around the femoral midshaft. A Gaussian noise filter was applied for the 
reconstruction, and a global binary threshold was manually established at 20 for 
trabecular analysis and 100 for cortical analysis. 
Histological analysis 
For histological preparations, samples were fixed in 4% paraformaldehyde for 48 
hours at 4°C, decalcified in 14% EDTA for 4 weeks and paraffin embedded. Samples 
were cut into 5 µm sections and stained with Hematoxylin/eosin or Masson’s trichrome. 
Statistical analysis  
Statistical analysis was performed using One-way ANOVA or Student's t test. 
Quantitative data are presented as means ± S.E.M. Differences were considered 
significant at *p<0.05, **p<0.01 and ***p<0.001. 
 
